Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
bevacizumab + irinotecan + oxaliplatin
- Development stage
- Unknown
- Lead developer
- Genentech
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
This is a combination therapy used primarily for metastatic colorectal cancer (mCRC). It combines bevacizumab, a humanized monoclonal antibody that inhibits vascular endothelial growth factor A (VEGF-A) to slow the growth of new blood vessels, with irinotecan and oxaliplatin, which are chemotherapy agents. This regimen is used in both first-line and second-line treatment settings for mCRC, with studies showing promising activity and significant improvements in response rates, progression-free survival, and overall survival.
02
Targets
Beyond the preview
Go deeper on bevacizumab + irinotecan + oxaliplatin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on bevacizumab + irinotecan + oxaliplatin.